title: Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.
abstract: BACKGROUND
  Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents.
  
  
  METHODS
  A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiple myeloma. We employed this combination as front-line chemoinduction therapy for a case of primary PCL.
  
  
  CONCLUSIONS
  Complete remission was achieved with rapid normalization of hematologic parameters. The combination of bortezomib, doxorubicin and dexamethasone demonstrates promise in the treatment of PCL.
authors.affiliation: Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. brunom@stanford.edu.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Chan
authors.forename: Tracy
authors.initials: T
authors.lastname: George
authors.forename: Athena M
authors.initials: AM
authors.lastname: Cherry
authors.forename: Bruno C
authors.initials: BC
authors.lastname: Medeiros